High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

SIMPLE SUMMARY: Tumor mutation burden (TMB) represents the mutational load in the tumor cell genome and serves as a surrogate marker for tumor neoantigen production and potential immunogenicity. TMB has been widely explored as a complementary or alternative biomarker for immune checkpoint inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Ji-Youn, Park, Dong-Won, Lee, Seung-Hyeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495802/
https://www.ncbi.nlm.nih.gov/pubmed/36140210
http://dx.doi.org/10.3390/biomedicines10092109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495802/
https://www.ncbi.nlm.nih.gov/pubmed/36140210
http://dx.doi.org/10.3390/biomedicines10092109

Ejemplares similares